ShoreHaven Wealth Partners’s Ascendis Pharma A/S ASND Stock Holding History

ShoreHaven Wealth Partners’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-752	Closed	-$97K	–	73
2021 Q1	$97K	Buy	752 +203	+37%	+$30.9K	0.05%	84
2020 Q4	$92K	Buy	+549	New	+$90.8K	0.05%	82

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

ShoreHaven Wealth Partners's ASND Position: Q2 2021 in Review

ShoreHaven Wealth Partners sold out of Ascendis Pharma A/S (ASND) in Q2 2021, closing a stake of 752 shares — an estimated $97K sold.

ShoreHaven Wealth Partners first reported a position in ASND in Q4 2020 and held it in 2 quarters. The position peaked at $97K in Q1 2021. 171 funds tracked by Wall St. Rank hold ASND as of Q2 2021.

ShoreHaven Wealth Partners reported no remaining Ascendis Pharma A/S position as of Q2 2021 after selling out during the quarter.
ShoreHaven Wealth Partners sold 752 Ascendis Pharma A/S shares in Q2 2021, an estimated $97K.
ShoreHaven Wealth Partners first reported a position in Ascendis Pharma A/S in Q4 2020 and held it in 2 quarters.
ShoreHaven Wealth Partners's Ascendis Pharma A/S position peaked at $97K in Q1 2021.
171 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2021.

Based on ShoreHaven Wealth Partners's 13F filing for Q2 2021, filed 16 Aug 2021.